Abatacept

Reduce direct handling to a minimum and wear appropriate personal protective equipment

Abatacept dosing is weight based; ensure accuracy of documented weight before administration

CAUTION: High Administration Risk Rating

Form & Storage	Powder for concentrate for solution for infusion Pack includes a silicone free syringe Refrigerate unopened vials at 2 - 8°C & protect from light.
Reconstitution	• Using the silicone-free syringe provided, reconstitute each vial with 10mL water for injections, directing the stream to the wall of the vial. • Remove the syringe and needle before swirling and rotating the vial gently to minimise foam formation; do not shake. • Once the powder has dissolved, vent the vial with a needle to dissipate any foam. The reconstituted solution (25mg/mL) requires further dilution before administration. • See **PPG-CUH-CUH-243** Policy Procedure and Guidelines for Management of Patients Attending CUH Infusion Unit for Intravenous Therapy CUH for more information
Compatibility & Stability	Sodium chloride 0.9%
Administration	**IV Infusion** • Dilute required dose to a total volume of 100mL with sodium chloride 0.9%. • Remove a volume of sodium chloride 0.9% from a 100mL infusion bag or bottle equal to the volume of the reconstituted dose required. • Using the same silicone-free disposable syringe as before, slowly add the reconstituted dose to the infusion container and gently mix the solution. The final concentration of abatacept should be no more than 10mg/mL • Give over 30 minutes through a low-protein-binding **filter** (0.2 to 1.2micron). • See **PPG-CUH-CUH-243** Policy Procedure and Guidelines for Management of Patients Attending CUH Infusion Unit for Intravenous Therapy CUH for more information
Documentation Requirements	Document batch numbers and expiry dates of vials in medical notes.
Adverse Drug Reactions	Medicinal products for the treatment of hypersensitivity reactions, e.g. adrenaline, oxygen, antihistamines and corticosteroids should be available for immediate use in the event of an allergic reaction during administration of all infusions.
Disposal	Dispose used vials, infusion bag and administration set in purple-lidded bins.
Additional Information	• Orencia® contains maltose. Medicinal products containing maltose can interfere with the readings of blood glucose monitors that use test strips with glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ). ACCU-CHEK Inform II (stocked in CUH) that are labelled with a green symbol on the outer box do not have a clinically relevant maltose interference.

Information relates to Orencia® manufactured by BMS.

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542